New NGS Panels for the Diagnosis of Inherited Cardiomyopathies
Paragraphs

June 2026 News

 

Two new high-throughput targeted sequencing (NGS) panels for inherited cardiac diseases and genetic cardiac rhythm disorders are now reimbursed in France.

 

Supported by recommendations from the French National Authority for Health (HAS), these new panels expand access to genetic diagnosis for patients with inherited cardiomyopathies, including hypertrophic (HCM), dilated (DCM), arrhythmogenic (ARVC), restrictive (RCM) and left ventricular non-compaction forms (LVNC), helping to support earlier diagnosis and optimized patient management.

Proposed Panels

 

18-Gene Panel – HCM (Hypertrophic Cardiomyopathy)

Genes analyzed: ACTC1, ACTN2, ALPK3, FHOD3, FHL1, FLNC, GLA, LAMP2, MYBPC3, MYH7, MYL2, MYL3, PRKAG2, TNNC1, TNNI3, TNNT2, TPM1, TTR

 

48-Gene Panel – Multiple Cardiomyopathy Phenotypes (Cardiac Disease)

Genes analyzed: ACTC1, ACTN2, ALPK3, BAG3, CSRP3, DES, DMD, DSC2, DSG2, DSP, EMD, FHL1, FHOD3, FLNC, GAA, GLA, JPH2, JUP, KRAS, LAMP2, LMNA, MYBPC3, MYH7, MYL2, MYL3, MYPN, NEXN, NKX2-5, PKP2, PLN, PRKAG2, PTPN11, RAF1, RBM20, RYR2, SCN5A, SOS1, TAFAZZIN, TBX5, TBX20, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR, VCL

Which NGS Panel Is Recommended for Each Clinical Indication?

    Suspected Hereditary Hypertrophic Cardiomyopathy (HCM) Phenotype with Inconclusive Clinical Evaluation?

    18-Gene Panel – HCM as a First-Line Test.

    Negative 18-Gene HCM Panel result with persistent genetic suspicion ?

    48-Gene Panel – Diverse Phenotypes as a Second-Line Test.

    Suspected Hereditary Cardiomyopathy (DCM / ARVC / RCM / LVNC) with Inconclusive Clinical Evaluation?

    48-Gene Panel – Multiple Cardiomyopathy Phenotypes as a First-Line Test.

    Amyloidosis (TTR), Fabry Disease, or Laminopathy with Negative Monogenic Testing?

    48-Gene Panel – Diverse Phenotypes as a Second-Line Test

Text

*Following the revision of the French Bioethics Law, a copy of the patient's written informed consent for genetic testing must be submitted with every test request.
(French Public Health Code, Article R1131-4-2; Decree No. 2023-1426 of December 30, 2023).

Cerba is an ISO 15189-accredited laboratory authorized to perform genetic testing of individual genetic characteristics.

Title

References

Text
  • UNCAM Decision of April 28, 2026, NOR: SFHU2613531S – Official Journal of June 2, 2026, Text No. 35 of 101
  • HAS Opinion No. 2025.0006/AC/SEAP of February 13, 2025 – Targeted High-Throughput Sequencing of Gene Panels for the Diagnosis of Inherited Cardiomyopathies
  • HAS Health Technology Assessment Report No. 2025.0045/DC/SEAP of February 13, 2025
  • HAS Opinion No. 2024.0061/AC/SEAP of September 26, 2024
  • French Social Security Code, Articles L. 162-1-7, L. 162-1-7-1 and R. 162-52